Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.59)
# 224
Out of 5,091 analysts
66
Total ratings
63.83%
Success rate
20.9%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $14.95 | +33.78% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $72.86 | +4.31% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $10.71 | +30.72% | 1 | Aug 4, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $28.36 | +9.31% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $17.47 | -48.48% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $32.22 | +2.42% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $160.81 | +18.15% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $99.79 | +0.21% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $20.01 | -5.05% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $392.75 | -0.70% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $77.04 | -28.61% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $104.17 | -47.20% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $142.44 | +12.33% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $568.21 | +17.91% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $7.07 | +182.89% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,381.37 | +1.35% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.32 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $46.00 | +95.65% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $224.48 | +20.28% | 4 | Dec 20, 2023 |
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $14.95
Upside: +33.78%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $72.86
Upside: +4.31%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $10.71
Upside: +30.72%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $28.36
Upside: +9.31%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $17.47
Upside: -48.48%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $32.22
Upside: +2.42%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $160.81
Upside: +18.15%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $99.79
Upside: +0.21%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $20.01
Upside: -5.05%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $392.75
Upside: -0.70%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $77.04
Upside: -28.61%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $104.17
Upside: -47.20%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $142.44
Upside: +12.33%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $568.21
Upside: +17.91%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $7.07
Upside: +182.89%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,381.37
Upside: +1.35%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.32
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $46.00
Upside: +95.65%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $224.48
Upside: +20.28%